Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Catabasis Pharma (CATB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 40,914
  • Shares Outstanding, K 22,480
  • Annual Sales, $ 0 K
  • Annual Income, $ -36,060 K
  • 36-Month Beta 1.14
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.87

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.20 +51.67%
on 08/24/17
1.89 -3.70%
on 09/21/17
+0.61 (+50.41%)
since 08/22/17
3-Month
1.09 +66.97%
on 07/21/17
1.89 -3.70%
on 09/21/17
+0.52 (+40.00%)
since 06/22/17
52-Week
1.08 +68.52%
on 02/01/17
7.89 -76.93%
on 09/29/16
-3.18 (-63.60%)
since 09/22/16

Most Recent Stories

More News
Catabasis Pharmaceuticals to Present Results from the Open-Label Extension of the MoveDMD(R) Phase 2 Trial of Edasalonexent in Duchenne Muscular Dystrophy in a Late Breaking Session of the World Muscle Society

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that the Company will present results from the open-label extension of the...

CATB : 1.82 (+1.68%)
Top Ranked Momentum Stocks to Buy for September 11th

Top Ranked Momentum Stocks to Buy for September 11th

CATB : 1.82 (+1.68%)
KMX : 74.19 (+7.77%)
ROST : 60.89 (-0.03%)
REGN : 432.72 (-0.17%)
Sarepta's Golodirsen Positive in DMD Study, Shares Soar

Sarepta's (SRPT) Duchenne Muscular Dystrophy candidate, Golodirsen, achieved positive muscle biopsy results in first in-human study. Shares surged in response.

CATB : 1.82 (+1.68%)
SRPT : 45.17 (-4.10%)
SMMT : 12.68 (+0.36%)
BMRN : 94.95 (+1.64%)
Catabasis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Reviews Business Progress

-- Preclinical Data Support CAT-5571 as a Potential Treatment to Enhance Host Defenses by Restoring Autophagy in Cystic Fibrosis --

CATB : 1.82 (+1.68%)
Investor Network: Catabasis Pharmaceuticals Inc to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 10, 2017 / Catabasis Pharmaceuticals Inc (NASDAQ: CATB) will be discussing their earnings results in their Q2 Earnings Call to be held on Thursday, August 10, 2017 at...

CATB : 1.82 (+1.68%)
Catabasis Pharmaceuticals to Present at 2017 Wedbush PacGrow Healthcare Conference

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate...

CATB : 1.82 (+1.68%)
Catabasis Pharmaceuticals to Report Second Quarter 2017 Financial Results and Recent Corporate Developments on Thursday, August 10

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report second quarter 2017 financial results after the NASDAQ Global Market close on...

CATB : 1.82 (+1.68%)
Sarepta Appoints Ex-Allergan Executive as CEO and President

Sarepta Therapeutics, Inc. (SRPT) announced the appointment of Douglas S. Ingram as the new chief executive officer (CEO).

CATB : 1.82 (+1.68%)
SRPT : 45.17 (-4.10%)
AGN : 204.65 (+0.98%)
REGN : 432.72 (-0.17%)
Catabasis Pharmaceuticals to Present Results from the MoveDMD(R) Trial of Edasalonexent (CAT-1004) at the 2017 PPMD Annual Connect Conference

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present data from Part A and Part B of the MoveDMD trial of...

CATB : 1.82 (+1.68%)
Pre-Market Technical Recap on Biotech Stocks -- Array BioPharma, Catabasis Pharma, Cerulean Pharma, and Immunomedics

If you want a stock review on ARRY, CATB, CERU, or IMMU then come over to http://dailystocktracker.com/register/ and sign up for your free customized reports today. DailyStockTracker.com has initiated...

CATB : 1.82 (+1.68%)
ARRY : 11.32 (-1.31%)
CERU : 0.66 (+4.76%)
IMMU : 11.47 (+0.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutics for treatment of inflammatory, immunological and metabolic diseases. Its product development pipeline includes CAT-1004, CAT-2000 series including CAT-2054...

See More

Support & Resistance

2nd Resistance Point 1.91
1st Resistance Point 1.87
Last Price 1.82
1st Support Level 1.76
2nd Support Level 1.69

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.